BCRX vs. CHCI
BCRX (BioCryst Pharmaceuticals, Inc.) and CHCI (Comstock Holding Companies, Inc.) are both stocks. BCRX operates in Biotechnology (Healthcare), while CHCI operates in Real Estate - Diversified (Real Estate). Over the past 10 years, BCRX returned 8.16%/yr vs 24.48%/yr for CHCI. Their 0.08 correlation means their historical movements had little consistent relationship.
Performance
BCRX vs. CHCI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BCRX achieves a 16.28% return, which is significantly lower than CHCI's 33.05% return. Over the past 10 years, BCRX has underperformed CHCI with an annualized return of 8.16%, while CHCI has yielded a comparatively higher 24.48% annualized return.
BCRX
- 1D
- 0.55%
- 1M
- -10.82%
- 6M
- 41.28%
- YTD
- 16.28%
- 1Y
- 8.49%
- 3Y*
- 6.07%
- 5Y*
- -12.43%
- 10Y*
- 8.16%
- ALL TIME*
- 1.16%
CHCI
- 1D
- 0.91%
- 1M
- -4.86%
- 6M
- 36.33%
- YTD
- 33.05%
- 1Y
- 24.18%
- 3Y*
- 49.14%
- 5Y*
- 19.18%
- 10Y*
- 24.48%
- ALL TIME*
- -9.47%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $28.03M | $37.18M | $45.64M | |
| $424.17K | $426.27K | $436.24K |
BCRX vs. CHCI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BCRX BioCryst Pharmaceuticals, Inc. | 16.28% | 3.72% | 25.54% | -47.82% | -17.11% | 85.91% | 115.94% | -57.25% | 64.36% | -22.43% |
CHCI Comstock Holding Companies, Inc. | 33.05% | 43.81% | 82.32% | 4.28% | -12.37% | 53.00% | 62.02% | 16.46% | -1.18% | -5.56% |
Correlation
The correlation between BCRX and CHCI is 0.13, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.13 |
Correlation (3Y) Balances recent behavior with more history. | 0.04 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.06 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.04 |
Correlation (All Time) Calculated using the full available price history since Dec 14, 2004 | 0.08 |
Fundamentals
BCRX:
$2.31B
CHCI:
$155.20M
BCRX:
-$1.63
CHCI:
$1.66
BCRX:
2.28
CHCI:
2.40
BCRX:
$940.61M
CHCI:
$67.67M
BCRX:
$221.20M
CHCI:
$15.13M
BCRX:
-$303.18M
CHCI:
$13.31M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BCRX vs. CHCI — Risk / Return Rank
BCRX
CHCI
BCRX vs. CHCI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and Comstock Holding Companies, Inc. (CHCI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BCRX | CHCI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.18 | ||
| Sortino ratioReturn per unit of downside risk | -0.36 | ||
| Omega ratioGain probability vs. loss probability | 1.07 | 1.13 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 0.31 | 0.55 | -0.24 |
| Martin ratioReturn relative to average drawdown | 0.64 | 0.98 | -0.34 |
Loading charts...
Drawdowns
BCRX vs. CHCI - Drawdown Comparison
The maximum BCRX drawdown since its inception was -97.74%, roughly equal to the maximum CHCI drawdown of -99.80%. Use the drawdown chart below to compare losses from any high point for BCRX and CHCI.
Loading charts...
Drawdown Indicators
| BCRX | CHCI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.74% | -99.80% | +2.06% |
Max Drawdown (1Y)Largest decline over 1 year | -27.44% | -44.23% | +16.79% |
Max Drawdown (3Y)Largest decline over 3 years | -46.01% | -47.93% | +1.92% |
Max Drawdown (5Y)Largest decline over 5 years | -79.10% | -47.93% | -31.17% |
Max Drawdown (10Y)Largest decline over 10 years | -83.69% | -75.34% | -8.35% |
Current DrawdownCurrent decline from peak | -72.62% | -92.56% | +19.94% |
Average DrawdownAverage peak-to-trough decline | -69.65% | -92.09% | +22.44% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 13.21% | 24.64% | -11.43% |
Volatility
BCRX vs. CHCI - Volatility Comparison
BioCryst Pharmaceuticals, Inc. (BCRX) and Comstock Holding Companies, Inc. (CHCI) have volatilities of 11.22% and 11.58%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BCRX | CHCI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.22% | 11.58% | -0.36% |
Volatility (6M)Calculated over the trailing 6-month period | 35.77% | 41.92% | -6.15% |
Volatility (1Y)Calculated over the trailing 1-year period | 46.22% | 66.16% | -19.94% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 62.12% | 61.32% | +0.80% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 72.50% | 92.62% | -20.12% |
Dividends
BCRX vs. CHCI - Dividend Comparison
Neither BCRX nor CHCI has paid dividends to shareholders.
Financials
BCRX vs. CHCI - Financials Comparison
This section allows you to compare key financial metrics between BioCryst Pharmaceuticals, Inc. and Comstock Holding Companies, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BCRX vs. CHCI - Profitability Comparison
BCRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, BioCryst Pharmaceuticals, Inc. reported a gross profit of 214.41M and revenue of 218.25M. Therefore, the gross margin over that period was 98.2%.
CHCI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Comstock Holding Companies, Inc. reported a gross profit of 2.78M and revenue of 17.45M. Therefore, the gross margin over that period was 15.9%.
BCRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, BioCryst Pharmaceuticals, Inc. reported an operating income of 98.47M and revenue of 218.25M, resulting in an operating margin of 45.1%.
CHCI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Comstock Holding Companies, Inc. reported an operating income of 1.54M and revenue of 17.45M, resulting in an operating margin of 8.8%.
BCRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, BioCryst Pharmaceuticals, Inc. reported a net income of 78.40M and revenue of 218.25M, resulting in a net margin of 35.9%.
CHCI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Comstock Holding Companies, Inc. reported a net income of 1.99M and revenue of 17.45M, resulting in a net margin of 11.4%.
Frequently Asked Questions
BCRX and CHCI have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CHCI has higher volatility (11.58%) compared to BCRX (11.22%). In terms of maximum drawdown, BCRX dropped -97.74% vs CHCI's -99.80%.
CHCI currently has the higher Sharpe Ratio (0.37 vs 0.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BCRX and CHCI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer